KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBIT (2016 - 2025)

Historic EBIT for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to $131.7 million.

  • Alnylam Pharmaceuticals' EBIT rose 22525.6% to $131.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $501.6 million, marking a year-over-year increase of 38356.16%. This contributed to the annual value of $501.6 million for FY2025, which is 38356.16% up from last year.
  • Alnylam Pharmaceuticals' EBIT amounted to $131.7 million in Q4 2025, which was up 22525.6% from $368.0 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' EBIT registered a high of $368.0 million during Q3 2025, and its lowest value of -$258.0 million during Q3 2022.
  • Over the past 5 years, Alnylam Pharmaceuticals' median EBIT value was -$131.3 million (recorded in 2021), while the average stood at -$72.6 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' EBIT crashed by 13595.93% in 2024 and then soared by 57848.9% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' EBIT stood at -$194.6 million in 2021, then increased by 3.06% to -$188.6 million in 2022, then surged by 38.28% to -$116.4 million in 2023, then increased by 9.66% to -$105.2 million in 2024, then surged by 225.26% to $131.7 million in 2025.
  • Its EBIT was $131.7 million in Q4 2025, compared to $368.0 million in Q3 2025 and -$16.2 million in Q2 2025.